Innovations for Substance Use Disorders

Have you wondered how to leverage Virtual Reality to combat opioid use disorder (OUD)? Come to our next webinar on May 23, 12 PM, ET, to learn how I4SUD alum and 2023 NIDA “$100,000 Start a SUD Startup” Challenge winner Dr. Lola Akintola, Ph.D., uses virtual reality to mitigate OUD. Register here: https://lnkd.in/eKFzDrU3

A new study demonstrated that Extended-release buprenorphine (XR-Bup) was associated with a reduction in ED use six months after initiation, indicating a potential increase in patient adherence and a reduction in healthcare system costs overall (https://lnkd.in/e5XpSMnZ). Incremental or sustaining drug innovations like XR-Bup can disrupt the market and create enormous value for stakeholders. Ideas don't always have to be disruptive to create impact. Whether you have an idea for an incremental or a disruptive innovation, our program can help you identify how to move it into the market. Apply today - https://lnkd.in/e9FiW56p

If you missed our recent webinar titled "Elements of a Commercialization Plan: A Primer" by Dr. Phan, Alonzo, and Virginia Decker, Professor of Strategy and Entrepreneurship at the Johns Hopkins Carey Business School, do not worry! You can view the recording and learn all about what you need to commercialize your next idea! Link to recording: https://lnkd.in/eppjyNMS

A recent study published in JAMA revealed that 11.4% of 12th graders in their study reported using Δ8-THC in the past year, 30.4% reported marijuana use in the past year, and notably, marijuana use did not differ by cannabis policies. At I4SUD 2023, Dr. Marc Fishman, a national expert on adolescent addiction treatment and program development, underscored the importance of the importance of understanding and addressing substance use trends among adolescents. Apply to our program if you have an idea you'd like to commercialize! Learn how in our webinar this Thursday - https://lnkd.in/evFMtgGM Link to study: https://lnkd.in/eXic2Vj9 Link to the I4SUD application: https://lnkd.in/e9FiW56p #CannabisResearch #AdolescentHealth

Calling all Academic Researchers! Are you ready to turn your research projects into translatable products or services with real-world impact? Join us for a dynamic webinar on "Elements of a Commercialization Plan" to learn how to bridge the gap between academia and entrepreneurship. Save the Date: April 25, 2024, 12 PM - 1 PM ET Take advantage of this chance to revolutionize your approach to research commercialization! Register Now! https://lnkd.in/evFMtgGM #AcademicEntrepreneurship #ResearchCommercialization #WebinarAlert

Check out this new personal view in The Lancet by our Director, Kelly E. Dunn, Ph.D., M.B.A. (at DrKellyDunn). If you are working on a new medication for OUD and want to understand how to get it to those who need it the most, check out our program - https://www.i4sud.com/

Did you miss our webinar on market gaps in Xylazine led by Dr. Kelly E. Dunn, Ph.D., M.B.A. (at DrKellyDunn) on March 21? Don't worry; it is now available on our website. Watch here: https://lnkd.in/eZh4-mjj.

In our April webinar, Alonzo and Virginia Decker, Professor of Strategy and Entrepreneurship Dr. Phil Phan (https://lnkd.in/esn8w-pj), will discuss the essential components necessary for a successful commercialization plan. If you are an academic researcher and have thought about making an impact using your innovative solutions, join us to learn how to navigate the complexities of bringing a product to market. From market analysis to distribution channels and funding strategies to marketing tactics, Dr. Phan will provide invaluable insights and practical tips to help you navigate the path to commercial success. Finally, he will discuss the Innovations for Substance Use Disorders (I4SUD) program, which can help you bring these ideas and innovations to life! April 25, 12 - 1 PM ET Register here: https://lnkd.in/evFMtgGM #entrepreneurship #substanceusedisorders #researchtranslation

One more day until our webinar. Register NOW if you haven't already!

The opioid crisis has taken a concerning turn with the emergence of xylazine as an adulterant in fentanyl. Xylazine is a significant threat to public health, and a recent study shed light on the effects of xylazine when combined with fentanyl, urging urgent research. Studies like these underscore the urgent need for solutions and translational research. Link to paper - https://lnkd.in/eUyhgyYK Join Kelly E. Dunn, Ph.D., M.B.A. (at DrKellyDunn), one of the co-authors of this study and the Director of the I4SUD program, at a special webinar titled "Xylazine: Where are the Market Gaps?" on March 21, at 12 PM ET. Register: https://lnkd.in/e9pn8AjN #innovations #entrepreneurship #substanceusedisorders